BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China

Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on deve...

Full "IntellAsia: Resources" article